A Phase 2 proof-of-concept study of CNSA-001 for the treatment of Phenylketonuria (PKU)
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs CNSA-001 (Primary)
- Indications Phenylketonuria
- Focus Proof of concept; Therapeutic Use
- 09 Jan 2018 New trial record
- 08 Jan 2018 According to a Retrophin media release, results are expected in early 2019.
- 05 Jan 2018 According to a Retrophin media release, Censa Pharmaceuticals is planning to start this trial in mid-2018.